Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Entrada Therapeutics, Inc. (TRDA : NSDQ)

• Company Description    Entrada Therapeutics Inc. is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles(TM) to engage intracellular targets. Entrada Therapeutics Inc. is based in BOSTON. Number of Employees: 183

• Price / Volume Information    Yesterday's Closing Price: $6.91 Daily Weekly Monthly 20 Day Moving Average: 209,618 shares Shares Outstanding: 38.22 (millions) Market Capitalization: $264.10 (millions) Beta: -0.09 52 Week High: $21.79 52 Week Low: $4.93 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 13.47% 10.49% 12 Week 31.12% 25.68% Year To Date -60.03% -65.07%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL One Design Center Place Suite 17-500 - Boston,MA 02210 USA ph: 857-520-9158 fax: - investors@entradatx.com http://www.entradatx.com

• General Corporate Information    Officers Dipal Doshi - Chief Executive Officer Kush M. Parmar - Chairman Kory Wentworth - Chief Financial Officer Gina Chapman - Director Peter S. Kim - Director Peer Information Entrada Therapeutics, Inc. (CORR.) Entrada Therapeutics, Inc. (RSPI) Entrada Therapeutics, Inc. (CGXP) Entrada Therapeutics, Inc. (BGEN) Entrada Therapeutics, Inc. (GTBP) Entrada Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 29384C108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/26/26 Share - Related Items Shares Outstanding: 38.22 Most Recent Split Date: (:1) Beta: -0.09 Market Capitalization: $264.10 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.08 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.59 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/26/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.77 Price/Cash Flow: 4.35 Price / Sales: 4.29 EPS Growth vs. Year Ago Period: -202.86% vs. Previous Quarter: -1.92% Sales Growth vs. Year Ago Period: -91.75% vs. Previous Quarter: -17.23% ROE 09/30/25 - -26.42 06/30/25 - -17.81 03/31/25 - 5.84 ROA 09/30/25 - -22.08 06/30/25 - -14.55 03/31/25 - 4.61 Current Ratio 09/30/25 - 14.08 06/30/25 - 18.64 03/31/25 - 21.88 Quick Ratio 09/30/25 - 14.08 06/30/25 - 18.64 03/31/25 - 21.88 Operating Margin 09/30/25 - -168.16 06/30/25 - -92.30 03/31/25 - 14.39 Net Margin 09/30/25 - -168.16 06/30/25 - -92.30 03/31/25 - 14.39 Pre-Tax Margin 09/30/25 - -169.85 06/30/25 - -96.76 03/31/25 - 13.82 Book Value 09/30/25 - 8.96 06/30/25 - 10.00 03/31/25 - 10.99 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©